Noachis Terra is using a novel technology to develop a coronavirus vaccine that is effective at protecting humans from the SARS-CoV-2 virus and preventing COVID-2019.
TECHNOLOGY
The
technology is based upon a stabilized protein construct maintaining a
prefusion state combine with a novel adjuvant to produce a robust immune
response to the SARS-CoV-2 virus. The vaccine itself will require one
to doses to provide a lifetime of immunity.
WHY THIS IS SIGNIFICANT
The
SARS-CoV-2 virus causes COVID-19 which has resulted in severe disease
and death in the human population. The highly stable prefusion construct
specifically focuses the immune system on the highly immunogenic region
of the virus that binds with the host cell for replication, resulting
in a robust immune response to the wild virus. The vaccine also has the
potential to provide a reaction to those already infected with the virus.
DATA/EVIDENCE
Laboratory
testing of the constructs shows highly immunogenic response to the
protein construct. Vaccine is in animal testing at present with
preliminary results showing high immunogenic response and potential
effectiveness against other coronavirus strains as well.
CLINICAL NEED
Since its discovery in
December 2019 in the Wuhan province of China, SARS-CoV-2 has been
discovered in more than 60 countries, close to 170,000 individuals and
has caused more than 6,500 deaths. Transmission rates are high. The
highest risk population for developing severe COVID-19 are those age 65
and older and those with underlying health conditions, such as diabetes
and cardiovascular disease.
MARKETS, INCUMBENTS AND COMPETITORS
There is no vaccine currently on the market preventing infection from
SARS-CoV-2. Multiple therapies are in research and development at
present.
MILESTONES
Technology is currently in animal testing. Pre-clinical development expected to commence April 2020, with IND filing in 3Q.
STATUS
The vaccine is currently in the pre-clinical stage with expectations of entering into clinical trials by October 2020.
